MX2021011764A - Solucion farmaceutica de adrenalina para un dispositivo de inyeccion. - Google Patents

Solucion farmaceutica de adrenalina para un dispositivo de inyeccion.

Info

Publication number
MX2021011764A
MX2021011764A MX2021011764A MX2021011764A MX2021011764A MX 2021011764 A MX2021011764 A MX 2021011764A MX 2021011764 A MX2021011764 A MX 2021011764A MX 2021011764 A MX2021011764 A MX 2021011764A MX 2021011764 A MX2021011764 A MX 2021011764A
Authority
MX
Mexico
Prior art keywords
adrenalin
pharmaceutical solution
injection device
relates
injection
Prior art date
Application number
MX2021011764A
Other languages
English (en)
Inventor
Eric Teillaud
Nicolas Baumard
Audrey Ressejeac
Original Assignee
Crossject
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossject filed Critical Crossject
Publication of MX2021011764A publication Critical patent/MX2021011764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con una solución farmacéutica de adrenalina que comprende por lo menos: - adrenalina o una sal farmacéuticamente aceptable de la misma; - TPGS de vitamina E; - un agente quelante; - un disolvente. La invención también se relaciona con el uso en el tratamiento de choques anafilácticos, ataques cardíacos, asma y malestares cardiocirculatorios. La invención también se relaciona con un kit de inyección que incluye un dispositivo de inyección y esta solución farmacéutica.
MX2021011764A 2019-04-18 2020-04-15 Solucion farmaceutica de adrenalina para un dispositivo de inyeccion. MX2021011764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1904166A FR3095122B1 (fr) 2019-04-18 2019-04-18 Solution pharmaceutique d’adrénaline pour dispositif d’injection
PCT/EP2020/060523 WO2020212381A1 (fr) 2019-04-18 2020-04-15 Solution pharmaceutique d'adrénaline pour dispositif d'injection

Publications (1)

Publication Number Publication Date
MX2021011764A true MX2021011764A (es) 2021-12-10

Family

ID=67384094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011764A MX2021011764A (es) 2019-04-18 2020-04-15 Solucion farmaceutica de adrenalina para un dispositivo de inyeccion.

Country Status (9)

Country Link
US (1) US11439605B2 (es)
EP (1) EP3955893B1 (es)
JP (1) JP7178512B2 (es)
BR (1) BR112021020857B1 (es)
CA (1) CA3132327C (es)
ES (1) ES2950184T3 (es)
FR (1) FR3095122B1 (es)
MX (1) MX2021011764A (es)
WO (1) WO2020212381A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779061B1 (fr) * 1998-04-14 2004-08-20 Pharmatop Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
FR2832063B1 (fr) * 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
FR3014317B1 (fr) * 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
US9119876B1 (en) * 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations

Also Published As

Publication number Publication date
EP3955893C0 (fr) 2023-06-07
EP3955893A1 (fr) 2022-02-23
BR112021020857B1 (pt) 2023-11-21
CA3132327A1 (fr) 2020-10-27
FR3095122A1 (fr) 2020-10-23
US11439605B2 (en) 2022-09-13
BR112021020857A2 (es) 2021-12-14
JP2022520898A (ja) 2022-04-01
US20220211643A1 (en) 2022-07-07
WO2020212381A1 (fr) 2020-10-22
CA3132327C (fr) 2023-12-12
FR3095122B1 (fr) 2021-04-09
JP7178512B2 (ja) 2022-11-25
ES2950184T3 (es) 2023-10-05
EP3955893B1 (fr) 2023-06-07

Similar Documents

Publication Publication Date Title
SA519401336B1 (ar) تركيبة صيدلية
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12020551425A1 (en) Rimegepant for cgrp related disorders
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
WO2016133903A3 (en) Combination therapy for cancer treatment
JOP20200336A1 (ar) طرق إعطاء مثبطات vmat2 معينة
MX2019003099A (es) Composicion farmaceutica.
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2019003097A (es) Composicion farmaceutica.
AR100368A1 (es) Tratamiento de trastornos respiratorios
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2021010022A (es) Composicion farmaceutica.
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2022001647A (es) Terapia de combinacion con vildagliptina y metformina.
MX2021011764A (es) Solucion farmaceutica de adrenalina para un dispositivo de inyeccion.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.